- Home
- / HilleVax
HilleVax
Stock Price
$1.9
2024-10-29
Market Capitalization
$95.1 M
2024-10-29
HilleVax Summary
Company Summary
- Overview
- HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
- Type
- Public
- Status
- Active
- Founded
- 2020
- HQ
- Boston, MA, US | view all locations
- Website
- https://www.hillevax.com/
- Cybersecurity rating
Table of Contents
Key People
Astrid Borkowski, Chief Medical Officer
Paul Bavier, General Counsel, Secretary & Chief Administrative Officer
LocationsView all
1 location detected
Boston, MA HQ
United States
75 State St Suite 100
HilleVax Financials
Summary Financials
- Net income (Q2, 2025)
- ($5.3M)
- Cash (Q2, 2025)
- $58.7M
- EBIT (Q2, 2025)
- ($7.0M)
- Enterprise value
- $60.0M